Therapies directed toward the central nervous system remain difficult to translate into
improved clinical outcomes. This is largely due to the blood–brain barrier (BBB), arguably …

Glioblastoma (GBM) is one of the most aggressive cancers of the brain. Despite extensive
research over the last several decades, the survival rates for GBM have not improved and …

The most emerging branch in pharmaceutical sciences known as “Pharmaceutical
nanotechnology” presents new tools, opportunities and scope, which are expected to have …

In this study, we introduced a targeting polymer poly (ethylene glycol)–folic acid (PEG–FA)
on the surface of polydopamine (PDA)-modified mesoporous silica nanoparticles (MSNs) to …

Nanoparticles as drug delivery system have received much attention in recent years,
especially for cancer treatment. In addition to improving the pharmacokinetics of the loaded …

Design and functionalization strategies for multifunctional nanocarriers (eg, nanoparticles,
micelles, polymersomes) based on biodegradable/biocompatible polymers intended to be …

The tumor microenvironment provides unique challenges for the delivery of
chemotherapeutic agents in doses that are effective while ensuring minimal systemic …

In recent years, there has been an unprecedented expansion in the field of nanomedicine
with the development of new nanoparticles for the diagnosis and treatment of cancer …

Cancer accounts for millions of deaths every year and, due to the increase and aging of the
world population, the number of new diagnosed cases is continuously rising. Although many …

Combining existing drug therapy is essential in developing new therapeutic agents in
disease prevention and treatment. In preclinical investigations, combined effect of certain …